Automation, Modularity Allow mAb Biotech To Cut Scale-Up Time

Original developers of biosolutions and products, especially those facing the debut of biosimilars in core markets, have an urgent imperative to reduce manufacturing costs via increased productivity and yields. In turn, this drives a wide range of business decisions, including capital investment, process choices and design, and equipment selection.

To this end, for example, biodevelopers are adopting more sophisticated processes, such as perfusion, to address low-titer cell lines and reduce raw material costs. They’re also seeking more sophisticated and flexible research and development (R&D) and process development (PD) capabilities in several ways by deploying equipment to enable simultaneous development of multiple products; automate rapid experimental design and implementation; optimize processes; and gain better analytical insights, especially for PAT and regulatory compliance.